New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib

References

• BukowskiRMCytokine therapy for metastatic renal cell carcinomaSemin Urol Oncol200119214815411354535
   PubMedGoogle Scholar
• TurnerKJMooreJWJonesAExpression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutationCancer Res200262102957296112019178
   PubMed Web of Science ®Google Scholar
• GruberMSimonMCHypoxia-inducible factors, hypoxia, and tumor angiogenesisCurr Opin Hematol200613316917416567961
   PubMed Web of Science ®Google Scholar
• TsuzukiYFukumuraDOosthuyseBKoikeCCarmelietPJainRKVascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha – hypoxia response element – VEGF cascade differentially regulates vascular response and growth rate in tumorsCancer Res200060226248625211103778
   PubMed Web of Science ®Google Scholar
• FukumuraDXavierRSugiuraTTumor induction of VEGF promoter activity in stromal cellsCell19989467157259753319
   PubMed Web of Science ®Google Scholar
• HippenstielSKrullMIkemannARisauWClaussMSuttorpNVEGF induces hyperpermeability by a direct action on endothelial cellsAm J Physiol19982745 Pt 1L678L6849612282
   PubMedGoogle Scholar
• CarmelietPVEGF as a key mediator of angiogenesis in cancerOncology200569Suppl 341016301830
   PubMed Web of Science ®Google Scholar
• EdgrenMLennernasBLarssonANilssonSSerum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomasAnticancer Res1999191B86987310216508
   PubMed Web of Science ®Google Scholar
• CliffordSCProwseAHAffaraNABuysCHMaherERInactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumorigenesisGenes Chromosomes Cancer19982232002099624531
   PubMed Web of Science ®Google Scholar
• ForsytheJAJiangBHIyerNVActivation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1Mol Cell Biol1996169460446138756616
   PubMed Web of Science ®Google Scholar
• KimWYKaelinWGRole of VHL gene mutation in human cancerJ Clin Oncol200422244991500415611513
   PubMed Web of Science ®Google Scholar
• YamakawaMLiuLXBelangerAJExpression of angiopoietins in renal epithelial and clear cell carcinoma cells: Regulation by hypoxia and participation in angiogenesisAm J Physiol Renal Physiol20042874F649F65715198927
   PubMed Web of Science ®Google Scholar
• RiniBIVascular endothelial growth factor-targeted therapy in metastatic renal cell carcinomaCancer2009115Suppl 102306231219402073
   PubMed Web of Science ®Google Scholar
• HudsonCCLiuMChiangGGRegulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycinMol Cell Biol200222207004701412242281
   PubMed Web of Science ®Google Scholar
• HarrisPABoloorACheungMDiscovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-m ethyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitorJ Med Chem200851154632464018620382
   PubMed Web of Science ®Google Scholar
• KumarRKnickVBRudolphSKPharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMol Cancer Ther200767201221
   Web of Science ®Google Scholar
• HurwitzHIDowlatiASainiSPhase I trial of pazopanib in patients with advanced cancerClin Cancer Res200915124220422719509175
   PubMed Web of Science ®Google Scholar
• HutsonTEDavisIDMachielsJPEfficacy and safety of pazopanib in patients with metastatic renal cell carcinomaJ Clin Oncol201020 28347548020008644
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized Phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol200927223584359019487381
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
   PubMed Web of Science ®Google Scholar
• MotzerRJMazumdarMBacikJBergWAmsterdamAFerraraJSurvival and prognostic stratification of 670 patients with advanced renal cell carcinomaJ Clin Oncol19991782530254010561319
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• KayAMotzerRFiglinRUpdated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC)ASCO Genitourinary Cancer Symposium2009 Feb 26–28Orlando, FL
   Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind Phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEBevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206J Clin Oncol200826335422542818936475
   PubMed Web of Science ®Google Scholar
• EscudierBBellmuntJNegrierSPhase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survivalJ Clin Oncol201028132144215020368553
   PubMed Web of Science ®Google Scholar
• LernerSEHawkinsCABluteMLDisease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgeryJ Urol19961556186818738618276
   PubMed Web of Science ®Google Scholar
• FrankIBluteMLLeibovichBCChevilleJCLohseCMZinckeHIndependent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohortJ Urol200517361889189215879769
   PubMed Web of Science ®Google Scholar
• ClarkJIAtkinsMBUrbaWJAdjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trialJ Clin Oncol200321163133314012810695
   PubMed Web of Science ®Google Scholar
• MessingEMManolaJWildingGPhase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trialJ Clin Oncol20032171214122212663707
   PubMed Web of Science ®Google Scholar
• SablinMPNegrierSRavaudASequential sorafenib and sunitinib for renal cell carcinomaJ Urol200918212934discussion 34.19447417
   PubMed Web of Science ®Google Scholar
• XuCFReckBHXueZPazopanib-induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphismBr J Cancer201027 10291371137720389299
   PubMed Web of Science ®Google Scholar
• BhargavaPEstevesBNosovDAUpdated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC)J Clin Oncol20092715SAbstr 5032
   Google Scholar
• Hu-LoweDDZouHYGrazziniMLNonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3Clin Cancer Res200814227272728319010843
   PubMed Web of Science ®Google Scholar
• MendelDBLairdADXinXIn vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationshipClin Cancer Res20039132733712538485
   PubMed Web of Science ®Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res200464197099710915466206
   PubMed Web of Science ®Google Scholar